Candriam S.C.A. Sells 13,542 Shares of Monopar Therapeutics Inc. $MNPR

Candriam S.C.A. lowered its position in Monopar Therapeutics Inc. (NASDAQ:MNPR) by 9.4% during the third quarter, HoldingsChannel reports. The firm owned 129,797 shares of the company’s stock after selling 13,542 shares during the period. Candriam S.C.A.’s holdings in Monopar Therapeutics were worth $10,379,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Siren L.L.C. lifted its stake in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after purchasing an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC grew its position in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after purchasing an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Monopar Therapeutics in the second quarter valued at approximately $7,124,000. Walleye Capital LLC acquired a new stake in shares of Monopar Therapeutics in the first quarter valued at approximately $3,458,000. Finally, Bank of America Corp DE lifted its position in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after buying an additional 53,336 shares in the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Stock Up 3.3%

MNPR stock opened at $73.75 on Tuesday. Monopar Therapeutics Inc. has a one year low of $50.07 and a one year high of $124.82. The firm’s 50 day moving average price is $86.12 and its 200-day moving average price is $77.41.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.02. As a group, research analysts expect that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. HC Wainwright boosted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. Morgan Stanley reiterated an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a report on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, October 15th. Finally, BTIG Research upped their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $122.78.

Insiders Place Their Bets

In other news, Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total value of $351,181.34. Following the transaction, the director owned 23,751 shares of the company’s stock, valued at $2,654,649.27. This represents a 11.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the transaction, the chief executive officer owned 99,267 shares of the company’s stock, valued at approximately $8,735,496. This represents a 22.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 51,920 shares of company stock worth $4,527,913. Company insiders own 9.70% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.